Search research articles
Contact Us
Filters
Showing results (391-400 of 441) with videos related to
Page
of 45
Sort By:
Journal of Hepatology
|
August 10, 2018
Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis
Nathalie Ganne-Carrié, Cendrine Chaffaut, Valérie Bourcier, et al.
Clinics and Research in Hepatology and Gastroenterology
|
June 30, 2020
Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort
Anais Vallet-Pichard, Jean-Michel Correas, Celine Dorival, et al.
Arthritis Care & Research
|
February 26, 2013
Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases
Nina Droz, Laurent Gilardin, Patrice Cacoub, et al.
Antiviral Therapy
|
June 28, 2013
Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C
Jean-Pierre Bronowicki, Stanislas Pol, Paul J Thuluvath, et al.
The Lancet. Infectious Diseases
|
June 21, 2012
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial
Stanislas Pol, Reem H Ghalib, Vinod K Rustgi, et al.
The New England Journal of Medicine
|
June 6, 2024
Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D
Tarik Asselah, Vladimir Chulanov, Pietro Lampertico, et al.
Alimentary Pharmacology & Therapeutics
|
October 26, 2021
Corrigendum
Stanislas Pol, Clovis Luzivika Nzinga, Céline Dorival, et al.
Journal of Hepatology
|
September 21, 2014
Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin
Jordan J Feld, Ira M Jacobson, Donald M Jensen, et al.
Gastroenterology
|
October 15, 2014
Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection
Gregory J Dore, Eric Lawitz, Christophe Hézode, et al.
Lancet (London, England)
|
August 1, 2014
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
Michael Manns, Stanislas Pol, Ira M Jacobson, et al.
Page
of 45
Search research articles
Search
Showing results (391-400 of 441) with videos related to
Sort By:
Page
of 45
Journal of Hepatology
|
August 10, 2018
Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis
Nathalie Ganne-Carrié, Cendrine Chaffaut, Valérie Bourcier, et al.
Clinics and Research in Hepatology and Gastroenterology
|
June 30, 2020
Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort
Anais Vallet-Pichard, Jean-Michel Correas, Celine Dorival, et al.
Arthritis Care & Research
|
February 26, 2013
Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases
Nina Droz, Laurent Gilardin, Patrice Cacoub, et al.
Antiviral Therapy
|
June 28, 2013
Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C
Jean-Pierre Bronowicki, Stanislas Pol, Paul J Thuluvath, et al.
The Lancet. Infectious Diseases
|
June 21, 2012
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial
Stanislas Pol, Reem H Ghalib, Vinod K Rustgi, et al.
The New England Journal of Medicine
|
June 6, 2024
Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D
Tarik Asselah, Vladimir Chulanov, Pietro Lampertico, et al.
Alimentary Pharmacology & Therapeutics
|
October 26, 2021
Corrigendum
Stanislas Pol, Clovis Luzivika Nzinga, Céline Dorival, et al.
Journal of Hepatology
|
September 21, 2014
Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin
Jordan J Feld, Ira M Jacobson, Donald M Jensen, et al.
Gastroenterology
|
October 15, 2014
Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection
Gregory J Dore, Eric Lawitz, Christophe Hézode, et al.
Lancet (London, England)
|
August 1, 2014
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
Michael Manns, Stanislas Pol, Ira M Jacobson, et al.
Page
of 45